Reaction: Tepotinib to 1 product

Reaction
Tepotinib
DB15133
Tepotinib M506 metabolite
DBMET03249
Reaction type
oxidation
Direction
Major circulating metabolite?
Yes
Spontaneous?
No
Activity
unknown
References
  1. Johne A, Scheible H, Becker A, van Lier JJ, Wolna P, Meyring M: Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers. Invest New Drugs. 2020 Oct;38(5):1507-1519. doi: 10.1007/s10637-020-00926-1. Epub 2020 Mar 27. [Article]
  2. FDA Approved Drug Products: Tepmetko (tepotinib) tablets for oral use [Link]
Comments
Not Available
Enzymes
EnzymeKmVmaxRole
Cytochrome P450 3A4Not AvailableNot Availableimplied
Cytochrome P450 2C8Not AvailableNot Availableimplied